Presentation is loading. Please wait.

Presentation is loading. Please wait.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Similar presentations


Presentation on theme: "Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate."— Presentation transcript:

1 Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate at 3 months, 6 months, 1 year and 2 years. Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate at 3 months, 6 months, 1 year and 2 years. ACR70/50/20, American College of Rheumatology 70%/50%/20% response criteria; CrI, credible interval; CRP, C-reactive protein; DAS28, Disease Activity Score including 28-joint count; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; FEM, fixed-effects model; LDA, low disease activity; MTX, methotrexate; REM, random-effects model; TNFi, tumour necrosis factor inhibitor. *ACR70 at 6 months was a prespecified primary endpoint. Roy Fleischmann et al. RMD Open 2017;3:e000371 Copyright © BMJ Publishing Group & EULAR. All rights reserved.


Download ppt "Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate."

Similar presentations


Ads by Google